Pioneering EV Therapeutics—
Creating the Future of Medicine.
Extracellular Vesicles (EVs)—Life-Woven Nanocapsules
Redefining Therapy.
Redefining Therapy.
Scroll Down
News
- 2025.09.11NEWS RELEASEBreaking the Black Box of EV Therapeutics: EXORPHIA’s CMC Strategy to Be Showcased at an International Summit
-
2025.08.20NEWS RELEASEEXORPHIA and ROHTO Pharmaceutical Enter into Strategic Alliance to Advance Extracellular Vesicle Production Technology
Collaboration combines complementary strengths in regenerative medicine - 2025.08.19NEWS RELEASEMicroRNA-4516 in EXORPHIA’s MSC-EVs Shown to Suppress Pulmonary Fibrosis – Findings Published in International Journal
- 2024.05.23NEWS RELEASEEXORPHIA partners with Kyoritsu Holdings and Kyoritsu Seiyaku to jointly develop exosome-based therapeutics for pets
- 2024.05.23NEWS RELEASEEXORPHIA Receives Positive Feedback from FDA on Pre-IND Meeting for EXP01 Phase 1/2 Clinical Trial in ARDS Patients
What
is
Exosome ?
is
Exosome ?
About Exosome
Exosomes are attracting attention as a new drug discovery modality. This page presents their characteristics and potential as a new therapeutic modality for intractable diseases.
Technology
Leveraging our four core technologies foundational to exosome drug discovery, we are advancing the creation, optimization, and evaluation of new drug candidates (assets) tailored to meet disease needs.
Company
We are a drug discovery startup that focuses on the potential of exosomes as new treatment options for intractable diseases. Unlike university-originated ventures, we were founded with a market-in approach.